Talu ai nei, na tatala aloaia ai e Novo Nordisk lana lipoti tau tupe 2022. O faʻamatalaga o loʻo faʻaalia ai o le aofaʻi o faʻatauga a Novo Nordisk i le 2022 o le a oʻo atu i le 176.954 piliona Danish krone (US $ 24.994 piliona, o le fesuiaiga o fesuiaiga o tupe na faʻalauiloaina i le lipoti faʻaletausaga, tutusa i lalo), i luga 26% tausaga i luga o le tausaga, o tupe mama galue o le a oʻo atu i le 74.809 piliona Danish krone (US $10.566 piliona), i luga 28% tausaga i lea tausaga, ma tupe mama o le a 55.525 piliona Danish krone (US $7.843 piliona), i luga 16% tausaga i le tausaga. E manaia tele le faatinoga.

O fea e sau ai le fa'atinoga mata'ina a Novo Nordisk? Ole tali ole GLP-1 analogue. I le pipeline oloa a le Novo Nordisk, e mafai ona vaevaeina oloa i ni ituaiga se fa: GLP-1 analogues, insulin ma analogues, coagulation factors ma isi metabolic hormones, faatasi ai ma le faatauina atu o le 83.371 piliona Danish krone ($ 11.176 piliona, e le aofia ai nila mamafa mamafa), 52.952 piliona Danish. krone ($7.479 piliona), 11.706 piliona Danish krone ($1.653 piliona) ma le 7.138 piliona Danish krone ($1.008 piliona), i le faasologa. Faatasi ai ma GLP-1 analogues, o le faʻatauga o le Liraglutide hypoglycemic tui ua faʻaitiitia i lea tausaga ma lea tausaga, aeSemaglutidee matua mata'utia, ma le aofa'i o fa'atauga e 10.882 piliona tala i le 2022.